Context: Prostate cancer (PC) with lymph node metastases (LN+) is relatively rare, whereas it is relatively common in disease with a Gleason score (GS) 8 to 10 and virtually never seen in PC with GS 6 or less.
It is most variable in GS 7 PC.
Objective: To determine clinicopathologic features associated with GS 7 PC with LN+ compared with a control group without lymph node metastases (LN-).
Design: We analyzed 184 GS 7 radical prostatectomies with LN+ and the same number of LN- Gleason-matched controls. The LN+ cases were GS 3 + 4 = 7 (n = 64; 34.8%), GS 4 + 3 = 7 (n = 66; 35.9%), GS 3 + 4 = 7 with tertiary 5 (n = 10; 5.4%), and GS 4 + 3 = 7 with tertiary 5 (n = 44; 23.9%).
Results: The LN+ cases demonstrated higher average values in preoperative prostate-specific antigen (12.2 versus 8.1 ng/mL), percentage of positive biopsy cores (59.1% versus 42.9%), prostate weight (54.4 versus 49.4 g), number of LNs submitted (12.7 versus 9.4), incidence of nonfocal extraprostatic extension (82.6% versus 63.6%), tumor volume (28.9% versus 14.8%), frequency of lymphovascular invasion (78.3% versus 38.6%), intraductal spread of carcinoma (42.4% versus 20.7%), incidence of satellite tumor foci (16.4% versus 4.3%), incidence of pT3b disease (49.5% versus 14.7%), and lymphovascular invasion in the seminal vesicles (52% versus 30%). There were differences in GS 4 patterns and cytology between LN+ and LN- cases, with the former having higher volumes of cribriform and poorly formed patterns, larger nuclei and nucleoli, and more-frequent macronucleoli. All P ≤ .05.
Conclusion: Gleason score 7 PC with LN+ has features highlighting a more-aggressive phenotype. These features can be assessed as prognostic markers in GS 7 disease on biopsy (eg, GS 4 pattern, intraductal spread, cytology) or at radical prostatectomies (all variables), even in men without LN dissection or LN- disease.
Kryvenko ON, Gupta NS, Virani N, Schultz D, Gomez J, Amin A, Lane Z, Epstein JI. Are you the author?
Department of Pathology, Henry Ford Hospital, Detroit, Michigan; Department of Pathology, University of Michigan, Ann Arbor, Michigan; Department of Pathology, Rhode Island Hospital, Providence; and the Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
Reference: Arch Pathol Lab Med. 2013 May;137(5):610-7.